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Abstract
This research analyzes the demographic determinants of testing uptake in a highly
facilitated cascade testing protocol pilot effort for families with inherited cancer-predisposing
mutations. The program provided no-cost genetic testing to the family members of mutation
carriers using direct contact, telephone genetic counseling, and mailed saliva kits. This
facilitated intervention resulted in high uptake of testing for second degree relatives and
reduced sex-based risk disclosure. Uptake rates were highest among females and older
individuals. Young Caucasian males were most likely to decline testing. Contact was limited for
non-Caucasian and international individuals with low English-language proficiency, resulting in
lower uptake rates for these groups. Overall, uptake rates were comparable to traditional
testing methods and conditional uptake rates were lower than expected. More work is needed
to improve upon facilitated testing methods and to elucidate why some facilitation tools may
lead to reduced testing uptake.

Introduction
For the majority of individuals who develop cancer, the causative mutations are somatic
and random, induced by chance events during DNA replication or spurred on by exposure to
environmental mutagens. However, mutations in genes that are critical for regulating the cell
cycle can also be inherited. Currently recognized heritable mutations account for about 10% of
cancer cases. An individual who inherits a genetic mutation is at an increased risk of developing
cancer in their lifetime, typically at a much younger age than the general population. The exact
cancer risks associated with these mutations vary by gene and tissue type. For example,
individuals who have inherited mutations associated with Lynch syndrome have up to an 80%
risk to develop colon cancer over their lifetime, markedly increased over the 5% risk in the
general population (Vasen et al., 2007, Hampel 2016). For females with mutations associated
with hereditary breast and ovarian cancer syndrome (HBOC), risk estimates range from about
40% to over an 80% lifetime risk of developing breast cancer and a 20-60% lifetime risk of
developing ovarian cancer (Berliner et al., 2013; Rebbeck et al., 2015).
Knowing gene status has a great number of benefits. Morbidity and mortality can be
reduced with proper surveillance (i.e. colonoscopies, mammograms, etc) to catch cancers at
early stages when treatment is more successful (Nelson et al., 2016). In some cases,
prophylactic surgeries are recommended to remove tissue before it develops malignancies
(Barrow et al., 2015; Berliner et al., 2013; Rebbeck et al., 2015). Gene status also informs cancer
treatment in individuals who have a cancer diagnosis. One of the most well-known examples is
the success of PARP inhibitors for treating ovarian cancer in BRCA1/2 mutation carriers
(Konecny & Kristeleit, 2016). Additionally, mutation carriers are at a higher risk for second

primaries, which can influence surgical treatment choices (Berliner et al., 2013). Mutation
status is important for reproductive planning. In-vitro fertilization and preimplantation genetic
diagnosis can be used to avoid transmission of a single mutation or, in rare cases, homozygous
transmission which can lead to conditions like Fanconi anemia or ataxia telangiectasia
(Woodson et al., 2014). Genetic information has a number of significant impacts on health
management decisions as well as other life choices.
Targeted genetic counseling and testing is needed to identify individuals with cancer
predisposing genetic variants. A patient may first be seen by a cancer genetics specialist due to
a concerning family history or an uncommon personal diagnosis (i.e. early onset or rare cancer).
If this person tests positive for a risk-elevating gene mutation, they are termed the index case
for their family. Identification of their gene status provides more accurate risk assessment for
close blood relations and opens the door for pre-symptomatic testing in first- and some seconddegree relatives (FDR & SDR). This process is known as cascade testing and is currently the most
efficient method for identifying mutation carriers before they develop cancer (Krawczak et al.,
2001; Ademi et al., 2014).
Cascade testing is a multistep process that requires cooperation and communication
between healthcare professionals, index patients, and other family members. Current practice
relies heavily on the index patient to disseminate the information they learned during genetic
counseling to their at-risk relatives, a process termed family contact. The index patient is also
responsible for encouraging relevant family to seek out genetic counseling and testing for
themselves (Landsbergen et al., 2005; Aktan-Collan et al., 2007; Barrow et al., 2015). This task is
often an unwelcomed burden to the proband and its continued success is influenced by

characteristics of the index patient, including their motivations, health beliefs, and familial
interactions (Landsbergen et al., 2005; Aktan-Collan et al., 2007; Barrow et al., 2015). Several
studies have shown that family contact returns disappointing levels of testing uptake, often
ranging from 20-45% (Suthers et al., 2006, Schlich-Bakker et al., 2007; Christiaans et al., 2008;
Fehniger et al., 2013; Sharaf et al., 2013, Menko et al., 2019). A number of factors have been
associated with these low levels. Index patients may be inhibited from informing any family
members due to concurrence of their own cancer diagnosis and treatment (Sermijn et al. 2004;
Barrow et al., 2015). If they are able to reach out, research on family communication of genetic
risks and the process of family contact has shown there is a loss of accuracy as information
originating from a genetic counselor is transferred and reinterpreted between family members
(Landsbergen et al. 2005; Vos et al. 2011a; Vos et al. 2011b). This can result in lower perceived
risks in relatives (Vos et al., 2011a). High proportions of index patients have reported that
disclosure is an “emotionally distressing” experience and that they do not feel prepared or
need additional guidance and support during the communication process (Gaff et al., 2005;
Landsbergen et al. 2005; Finlay et al., 2008). Burns and colleagues suggest that genetic
information, with its probabilistic nature and secondary findings, is too complex a subject to
burden an index patient with conveying and they highlight that interpersonal dynamics variably
influence how effective an index patient can be within their own family (2018). Some index
patients may have inconsistent contact, estrangement, or emotionally distant relationships
with some at-risk family members that impede difficult conversations about health
maintenance (McGivern et al., 2004). As a result, index patients often inform only a subset of
their at-risk family and studies have consistently identified preferential disclosure of

information to females and first-degree relatives (Aktan-Collan et al., 2000; McGivern et al.,
2004; Landsbergen et al., 2005; Finlay et al., 2008; Stoffel et al., 2008).
It has been suggested for many years that medical providers, and genetics specialists in
particular, do more to encourage cascade testing. Efforts to facilitate family contact have
consisted largely of descriptive letters detailing the familial variant and other educational
materials that index patients can provide to their family members (Sermijn et al., 2004; Suthers
et al., 2006; Aktan-Collan et al., 2007). Others have attempted to increase the education and
involvement of general practitioners (Barrow et al., 2013). However, these methods are still
one step removed for the individual at risk. Genetics specialists, at the permission of the index
patient, can contact family members directly. Ethical concerns have been raised regarding an
individual’s right not to be contacted by health professionals or to learn of their elevated
genetic risk but empirical studies on attitudes toward direct contact are universally positive
(Wright et al., 2002; Newson & Humphries, 2005; Suthers et al., 2006; Louter et al., 2017). Most
direct contact efforts have involved mailing letters to at-risk family, detailing their specific risks
and informing them about how to pursue testing. Other projects have employed genetics
specialists to approach family members in person or over the phone (Louter et al., 2017).
Regardless of the method, direct contact leads to higher levels of testing uptake (Suthers et al.,
2006; Menko et al., 2019).
Once someone has been informed of their genetic risk there are a variety of
characteristics and circumstances that have been associated with uptake of genetic testing.
Attitudinal features of the index individual, such as familiarity with cancer surveillance
practices, emotional preparedness, and satisfaction with their own testing experience are

known to influence cascade testing uptake rates for family members when family contact is
employed (Blandy et al., 2003; Landsbergen et al., 2005). Traits of individuals that have
positively correlated with uptake include high socioeconomic status and employment, higher
education, female sex, and being a parent or planning a family in the near future (Lerman et al.,
1996; Aktan-Collan et al., 2000; Hadley et al., 2003; Finlay et al., 2008; Cheung et al., 2010;
Sharaf et al., 2013). Older ages and some ethnic backgrounds (Asian and African American)
have corresponded to lower uptake across studies (Cheung et al., 2010; Fehniger et al., 2013).
Some family characteristics predict greater uptake as well, including a greater number of
affected first degree relatives and high levels of family support and knowledge about screening
procedures (Blandy et al. 2003; Hadley et al., 2003; Irons et al., 2017). However, current
research in this topic is inconsistent as some studies examining these same demographic and
familial variables have reported no patterns predicting uptake of genetic testing (McGivern et
al., 2004; Landsbergen et al., 2005; Christiaans et al., 2008; Fehniger et al., 2013). Individuals
may opt out of testing at any stage of the cascade process, but once someone receives genetic
counseling uptake rates tend to be very high, in excess of 90% by most reports (Hadley et al.,
2003; Christiaans et al., 2008; Hafertepen et al., 2017).
Mechanisms exist today to further facilitate testing by eliminating logistical barriers that
may prevent people from completing the process, like taking time off from work or traveling to
a medical center. One such mechanism is telephone genetic counseling. Research efforts
testing the effectiveness of telephone genetic counseling have repeatedly shown it to be
noninferior to traditional counseling in all areas (Kinney et al., 2014; Kinney et al., 2016). There
is a trend toward slightly lower uptake rates with telephone counseling (Butrick et al., 2015;

Schwartz et al., 2014). It is difficult to determine if this is because the additional individuals that
are reached via telephone counseling are already less likely to test or if it is a consequence of
the telephone counseling arrangement. Additionally, the advent of high throughput sequencing
has allowed noninvasive DNA collection, like saliva and buccal swabs, to become an adequate
source of DNA (Quinque et al., 2006; Pal et al., 2014). This allows for test kits to be sent and
returned through the mail without the need for travel or a blood draw.
Most work on correlates with cascade genetic testing uptake has relied on family
contact procedures or retrospective studies. Research supports the benefits of direct contact
and facilitated genetic testing opportunities. From 2017-2019, Weill Cornell Medical Center
piloted a highly facilitated cascade testing protocol for families with inherited cancerpredisposing mutations. This program provided no-cost genetic testing to the family members
of mutation carriers using direct contact, telephone genetic counseling, and mailed saliva kits.
This facilitated intervention design reduced many of the perceived barriers to genetic testing,
providing the opportunity to make informed decisions to a large number of at-risk individuals.
This project aims to identify variables that predict genetic testing uptake as well as variables
associated with individuals who were lost to testing at various stages of the project. We
hypothesize that the facilitated nature of this methodology will lead to high rates of testing
uptake and reduce the impact of index patients and biased risk disclosure on genetic testing
uptake. We predict that variables associated with the index patient, like degree of relation to
the index patient, and variables previously associated with biased risk disclosure, like sex, will
have limited impact on testing uptake due to direct contact through a health professional. We
predict that variables associated with individual decision-making, like parenthood or personal

cancer history will best predict testing uptake. Knowing which variables characterize individuals
who participate in cascade testing when logistical barriers are removed will help inform efforts
to increase and tailor the cancer genetic testing process.

Methods
Enrollment of index patients:
Index patients were identified from a pool of patients currently receiving cancer care at
Weill Cornell Medical Center (WCMC) during 2017/2018. Individuals who tested positive for a
cancer-predisposing mutation as part of their regular cancer care were approached by an
oncologist or study team member and offered enrollment in the study. The study team
recruited 30 subjects, both male and female, over 18-years-old with any confirmed pathogenic
mutation associated with an increased risk of cancer in any tissue(s). Subjects were contacted
by phone 6-9 months after receiving their test results to assess for any additional relatives who
pursued cascade testing outside of the study protocol.
Enrollment of at-risk family members:
Index patients worked with the study team to build a family pedigree and identify first
and second degree relatives (FDR & SDR) at high risk of carrying the mutation. Individuals were
considered “at-risk family members” if they met the following requirements:


not already tested



over 18-years-old



a FDR to the index patient or any known mutation carrier in the family



a SDR to the index patient if the intervening relative is deceased or has been contacted
and unequivocally declined



no intervening relative has tested negative

SDRs from the unaffected family lineage were not included if the lineage carrying the mutation
was clear from the pedigree (i.e. strong preponderance of cancer on one side of the family and
not the other). These criteria are fairly broad as they include SDRs and do not exclude family
members on the basis of location or language barriers. Many studies assess only FDR uptake
and discount geographically distant relatives due to the requirement of in-person genetic
counseling and testing.
The number of at-risk family members changed after the first identified family members
were contacted and tested. A number of FDRs of mutation carriers identified through study
testing reached out to the study team to request testing. The project was able to accommodate
all of these requests and so the number of at-risk family members was adjusted to include
relatives of mutation carriers that were identified over the course of the project following the
same rules listed above.
Index patients provided contact information for as many at-risk family members as they
were able. The study team attempted to contact identified relatives to offer them enrollment.
Efforts were made to contact international relations for whom contact information was
available as well as non-English speaking relations using telephone interpretation services
provided by WCMC. Contact was attempted a maximum of three times by any given modality –
i.e. three phone calls or three emails. All efforts were made to provide family members with the

means to contact the study team, via voicemail or email, if direct contact was unsuccessful.
Family members who were successfully contacted and agreed to participate in the study were
provided with telephone genetic counseling by certified genetic counselors at Invitae
Laboratories. Family members agreeing to genetic testing were mailed saliva kits by Invitae
staff with directions for completion and return of the sample in a prepaid envelope. Test results
were returned over the phone by the head oncologist on the study (MKF). Participants were
considered to have successfully completed testing once they received results. All participants
were contacted for follow-up at 6-9 months post genetic counseling session or results
disclosure (whichever was later) to assess for any additional relatives who pursued cascade
testing outside the study protocol. Follow-up contact was attempted a maximum of three times
by phone or email and participants were provided with contact information to reach out to
study staff if follow-up was unsuccessful.
Data analysis
Due to the loss of family members at various stages of the project, at-risk family members were
stratified into three outcome categories.
No Contact Group: this category contains at-risk individuals who were identified during
consultation with the index individual but contact with the study team was never accomplished,
either due to a lack of contact information or failure to respond to the study team after efforts
to reach out.
Informed Decline Group: this group includes individuals who spoke with the study team and
either declined to participate before genetic counseling, opted not to continue after genetic

counseling, or who agreed to testing but never returned their saliva sample. At follow-up it was
identified that most individuals who did not submit samples stated they had changed their
minds regarding testing.
Uptake Group: the uptake group included family members who successfully complete genetic
testing and received their results through the project or were identified on follow-up as having
gotten genetic testing outside the study.
Potential predictive variables associated with placement in any of these groups were
determined according to the data that was collected and these were classified into four basic
groupings
Table 1: Background, health history, and predictive variables considered in statistical analyses

Demographics
Age

b

Sex
Parenthood
Race
Education f
Personal History Cancer
Internationality
English proficiency

Index traits

Family history a

Genetic factors

Index Age

Num. of family members
with cancer
Num. cancer deaths
Family participation d

Penetrance c

Index Sex
Index Education
Degree of Relationship e

First and second degree relatives only
Binned value: 18-40, 41-60, 61+
c High penetrance genes: BRCA1/2, MSH2, MSH6, APC, PTEN
Moderate penetrance genes: ATM, BARD1, BRIP1, CHEK2, RAD51C/D, MUTYH
d Proportion of at-risk family + index case who completed testing, excluding the individual
e Degree of relationship to the index patient, defined as three groups: first degree, second degree, or third degree +
f Binned value: (1) high school or less, (2) college, (3) graduate school or more
a

b

Most data were logged as dichotomous categorical variables (yes/no) or by binning continuous
values. Age was binned into approximate 20-year blocks which provided reasonably even
distribution of the sample set across bins. Education was binned into three categories as high

school or less, college, and graduate school or above. Internationality was dichotomously
defined as living within the United States or not. English proficiency was determined by those
individuals who requested interpretation services when communicating with the genetic
counselor or when receiving their results. Details of English proficiency for those individuals
who were never contacted by study staff was collected from other family members whenever
possible. When considering family history variables, only FDRs and SDRs to the individual in
question were counted. The number of distinct family members with cancer, including typically
environmental cancers like lung cancer in a known smoker, were included in this metric. The
number of deaths in FDRs and SDRs that were a direct result of cancer, regardless of cancer
type, was counted. Family participation was measured by calculating the proportion of at-risk
individuals in the family (including the index patient) that successfully completed genetic
testing with the exception of the individual in question. This retrospective measure was
designed to capture the general acceptance of genetic testing that an individual may be
observing in their family situation as well as to test for consistency of behavior within families.
Penetrance was divided into high and moderately penetrant cancer predispositions. These
divisions are considered somewhat arbitrary but penetrance has been determined for particular
cancer types by the associated increase in relative risk as compared to the general population
(Easton et al. 2015, Tung et al. 2017). Moderate penetrance has been loosely defined as an
increase in average relative risk by 2-5 times over the general population and mutations are
considered highly penetrant for relative risks above that (Easton et al. 2015, Tung et al. 2017).
Mutations identified in the families in this project that are considered highly penetrant include:

BRCA1, BRCA2, PTEN, MSH6, MSH2, and APC. Mutations in the following genes have been
classified as moderately penetrant: ATM, BARD1, BRIP1, CHEK2, RAD51C, and MUTYH.
Data was analyzed using SPSS (version 25.0). Some variables were considered but
ultimately not included in data analysis due to sample size problems. The sex of the index
individual was not included because only one index patient was male. Additionally, education
was not a feasible metric for the no contact outcome group because this information was not
reliably available for 66 of the 67 individuals in that group.
Descriptive statistics were run on at-risk relatives using frequency measures and means
(Table 2). A subset of the sample was randomly chosen for chi-square analysis. Due to the
confounding effects of family groups, the statistical assumption of independent sampling would
not be met for the entire sample set. A random number generator was used to select one
individual as a representative from each family to generate a subset for statistical analysis. Chisquare analyses were run on all dichotomous variables to test for association with the three
outcome stratifications (no contact, informed decline, or uptake). Variables were also tested
against the dichotomous outcome of completion of genetic testing or not. The continuous
variables (number of family members with cancer, number of cancer deaths, and family
participation) were analyzed in a single logistical regression model for both outcome group and
dichotomous testing uptake.
Results
Thirty index patients were recruited into the study. According to our above criteria, 167
family members were identified to be at high-risk to be a mutation carrier, an average of 5.6
per index patient. The study team was provided with contact information for 101 family

members, an average of 3.4 per index patient. The study team attempted to contact all 101 and
were unable to establish contact with 12. Of the 89 family members who spoke with the team,
5 declined genetic testing and 84 agreed to genetic testing. Of those that agreed, 19 received
saliva test kits but never returned them and 64 returned their saliva kits and received their
results (one individual did not get conclusive results after two attempts, this person was
categorized in the uptake outcome group due to positive intention to test). On follow-up, an
additional 11 individuals were found to have pursued cascade genetic testing independently,
amounting to a total of 76 at-risk family members receiving cascade testing for the identified
mutation in the family. Of the 30 families, no contact was successfully achieved for any family
members in 6 families. In an additional 3 families, contact was made with at least a subset of atrisk family members but no one successfully completed testing. In 7 of the families, all of the
initially identified at-risk family members completed testing. Fourteen of the thirty families had
all members ultimately cluster within a single outcome group showing a consistency of
behavior within these families.
The final testing uptake rate was 46% of the identified high-risk family members.
Conditional uptake, defined as the proportion of individuals who pursued testing after contact
by the study team, was higher at 76%. For the individuals whose mutation status is known (64
of the 76) there were 37 negative results returned and 27 positive results.

Table 2: Descriptive statistics of identified at-risk family members and separated by outcome group.
All values are provided as number and percentage: n(%)
Characteristic
Age
18-40
41-60
61+
Sex
M
F
Relationship to Index
FDR
SDR
TDR+
Race
Caucasian
Non-Caucasian
Parent
Yes
No
Unknown
Education
High School or less
College
Graduate School +
Unknown
Personal History of
Cancer
Yes
No
Unknown
International
Yes
No
Unknown
English Proficiency
High
Low
Unknown
Penetrance
High
Moderate
Family members with
cancer (average)

At-risk Family
Members (n=167)

No Contact
Group (n=67)

Informed Decline Uptake Testing
Group (n=24)
Group (n=76)

51 (31)
65 (39)
51 (31)

24 (36)
24 (36)
19 (28)

10 (42)
11 (46)
3 (13)

17 (22)
30 (39)
29 (38)

91 (55)
76 (46)

38 (57)
29 (43)

17 (71)
7 (29)

36 (47)
40 (53)

97 (58)
42 (25)
28 (17)

40 (60)
18 (27)
9 (13)

13 (54)
3 (13)
8 (33)

46 (61)
21 (28)
9 (12)

110 (66)
57 (34)

37 (55)
30 (45)

21 (88)
3 (13)

52 (68)
24 (32)

88 (53)
65 (39)
14 (8)

20 (30)
33 (49)
14 (21)

13 (54)
11 (46)

55 (72)
21 (28)

1 (4)
7 (29)
16 (67)

15 (20)
23 (30)
23 (30)
15 (20)

1 (4)
23 (96)

64 (84)
12 (16)

24 (100)

11 (14)
62 (82)
3 (4)

16 (10)
31 (19)
39 (23)
81 (49)

66 (99)

70 (42)
89 (53)
8 (5)

5 (7)
54 (81)
8 (12)

38 (23)
122 (73)
7 (4)

27 (40)
36 (54)
4 (6)

126 (75)
35 (21)
6 (4)

36 (54)
25 (37)
6 (9)

23 (96)
1 (4)

67 (88)
9 (12)

125 (75)
42 (25)

45 (67)
22 (33)

20 (83)
4 (17)

60 (79)
16 (21)

3.3

3.0

3.3

3.4

1 (1)

Familial cancer deaths
(average)
Familial participation
rates (average)

1.6
0.53

1.5
0.29

2.0
0.53

1.7
0.74

with regard to testing outcome group for
descriptive purposes.

Table 2 includes the demographic
characteristics, family health history, and
gene-specific information for the entire
sample size as well as the three outcome
groups. Table 3 reports the relevant
characteristics assessed in the index
patients from each family. Supplemental
figures (S1-S11) graph the trends across the
entire sample of at-risk family members

Table 2: Characteristics of Index
Individuals. All values given in number
and percentage: n(%)
Characteristic
Index Group, n=30
Sex
M
1 (3)
F
29 (97)
Age
18-40
6 (20)
41-60
14 (47)
61+
10 (33)
History of Cancer
Yes
24 (80)
No
6 (20)
Education
High School or less
2 (7)
College
14 (47)
Graduate school +
14 (47)

The no contact group showed a strong positive association with being located outside
the USA, having low English language proficiency, being of non-Caucasian race, and a slightly
higher rate of moderately penetrant mutations. The informed decline group showed positive
association with younger age, male sex, and more distant degree of relationship to the index
patient. A weaker trend was seen with Caucasian race and graduate level education. The uptake
testing group was positively associated with increased family participation, older age, female

sex, living in the USA and proficiency with English. A weaker trend was seen with having a
personal cancer history and parenthood.

Randomized family subsample
The randomized subsample exhibited similar patterns to the full sample and included 13
individuals in the uptake testing outcome group, 4 individuals from the informed decline group,
and 13 individuals from the no contact group. Descriptive statistics on the subsample are shown
in Table 4. Chi square analysis on the randomly sampled sub-set of family members did not
support significant relationships between any demographic characteristics and testing outcome
group or on the dichotomous result of testing uptake or no testing uptake. Table 5 displays the
p-values for each variable.

Table 4: descriptive statistics on the
30-person subsample used for
statistical analyses. n(%)
Characteristic
Subset (n=30)
Age
18-40
8 (27)
41-60
13 (43)
61+
9 (30)
Sex
M
19 (63)
F
11 (37)
Relationship to Index
FDR
18 (60)
SDR
11 (37)
TDR+
1 (3)
Race
Caucasian
22 (73)
Non-Caucasian
8 (27)
Parent
Yes
20 (67)
No
8 (27)
Unknown
2 (7)
Education
High School or less
3 (10)
College
6 (20)
Graduate School +
5 (17)
Unknown
16 (53)
Personal History of
Cancer
Yes
2 (6.5)
No
26 (87)
Unknown
2 (6.5)
International
Yes
6 (20)
No
23 (77)
Unknown
1 (3)
English Proficiency
High
24 (83)
Low
5 (17)
Unknown
1 (3)
Penetrance
High
22 (73)
Moderate
8 (27)
Family members with
cancer (average)
3.3
Familial cancer
deaths (average)
1.3

Table 5: p-values from chi-squared analysis on the
randomly chosen subset of at-risk family members.
Testing predictive value of categorical descriptors
with specific outcome group result as well as the
completion of genetic testing generally. No
significant associations were revealed
Outcome
Variable
Testing Uptake
Groups
Age
0.08
0.08
Sex
0.63
0.35
Education
0.08
0.08
Race
0.99
0.70
Parenthood
0.33
0.28
Personal Hx Cancer
0.29
0.11
Internationality
0.30
0.52
English Proficiency
0.15
0.22
Degree of
0.25
0.46
Relationship
Index Age
0.45
0.24
Index Education
0.42
0.63
Penetrance
0.90
0.70

Simple binary logistic regression model for the continuous variables (number of family
members with cancer, number of cancer deaths, and family participation) on dichotomous
testing uptake showed a significance influence from familial participation (p=0.014) but no
significant
associations with the number of family members with cancer (p=0.166) or the number
of cancer deaths in the family (p=0.215). A multinomial logistic regression was done to predict
outcome group but the sample size was underpowered. No significant associations were found.
Discussion

This highly facilitated cascade testing design showed a level of genetic testing uptake
(46%) similar to levels that have been reported by other cascade testing initiatives, most of
which have ranged from 31-57% (Fehniger et al., 2013; Sharaf et al., 2013; Menko et al., 2019).
Comparison of testing uptake rates across studies is complicated by important differences in
methodologies. Studies vary in their methods for informing relatives of their risks, with some
attempting pure family-contact, some employing direct-contact methods, and others using a
blended approach (Suthers et al., 2006; Christiaans et al., 2008; Hafertepen et al., 2017). There
is considerable variability in how studies define “at-risk” relatives, with some projects
restricting this metric to FDRs only (Sharaf et al., 2013). Generally, testing uptake is found to be
negatively related to degree of relationship with the index patient and this may be a direct
consequence of the biased disclosure of risk to FDR during family contact (Blandy et al., 2003).
The prediction that uptake would not be influenced by degree of relation to the proband was
supported. In this protocol, testing uptake was not significantly different between first and

second degree relatives (p=0.25), as is so often seen in other research (McGivern et al., 2004;
Christiaans et al., 2008; Barrow et al., 2015). This is likely a result of the facilitated nature of
relative identification and direct contact by medical providers. There was a slightly increased
proportion of more distant relatives (third degree or more) in the informed decline outcome
group. Many of these relatives were contacted because of deceased intervening relatives, and
so their risks to carry pathogenic variants would be estimated to be lower, which may have
influenced the decision to decline testing.
Variables that did not display strong trends with any of the outcome groups include
penetrance and features of the index patient like index age and education. Penetrance is a
complicated concept and risk perceptions may be sufficiently elevated for all the genes
considered in this study. While ultimately it does seem that the index patient impacted
outcome grouping (detailed below particularly in reference to the no contact group) the
demographic characteristics we analyzed, like age and education, do not appear to capture the
relevant variability that may exist across index patients.
No Contact testing outcome
Several of the characteristics of the no contact testing outcome group are demographic
and not associated with individual decision making based on risks. The no contact testing
outcome group was more likely than other outcome groups to be non-Caucasian, live
internationally, and have lower English language proficiency. They were also more likely to not
be a parent and have no personal history of cancer. This group had the lowest levels of family
participation in general. There was no pattern observed with regard to age, sex, or degree of

relationship. The majority of the no contact group is comprised of individuals for whom contact
information was never obtained. The provision of contact information for at-risk relatives relied
on the index patient and discrepancies appeared in the abilities or willingness of different index
patients to reliably provide contact information. Index patients were far less likely to provide
the means to contact relatives who lived internationally and did not speak English. This fact
reinforces the importance of the index patient even in a highly facilitated testing framework.
Cascade testing requires medical providers to reach out to people who are not in their medical
system and so contact information can be difficult to acquire. It was at this early stage of the
program that the largest proportion of at-risk family members were lost to testing. Contact was
never attempted for 82% of this group; the remaining 18% did not return contact after it was
attempted. It is unclear if index individuals informed family members in advance that they
would be contacted by the study or how the levels of communication within families varied
with relation to outcomes.
Research on individuals who are difficult to contact is expectedly slim. Hafertepen and
colleagues were able to follow-up with a group of newly diagnosed breast cancer patients who
were referred for genetic counseling but never made an appointment (2017). They found that
these patients were under too much concurrent stress and did not feel like the genetic
counseling appointment was sufficiently important. Other work on patients who decline testing
prior to receiving genetic counseling has shown that these individuals feel this information is
not relevant for them and have a low-perceived risk (Schlich-Bakker et al., 2007). Follow-up
was not attempted with these individuals since consent was never acquired for participation in
the study, making additional inference into their motivations impossible within this protocol.

Informed Decline outcome group
Most of the characteristics that make the informed decline testing outcome group stand
out are associated with individual decision making and interpretation of risks. Informed
decliners were more likely to be younger, male, Caucasian, and more distantly related to the
index patient (third degree relatives or greater). They were also more highly educated on
average than the uptake group. Only one individual in this group had a personal history of
cancer and they were slightly less likely to be parents. Generally, these demographic patterns
are not surprising based on what has been noted in the literature. Younger males have been
reported to be less likely to participate in genetic testing (Barrow et al., 2015). Given the
unbalanced risks for males and females inherent to some predisposing gene mutations, this
pattern may reflect decreased perceived risks. Furthermore, upon follow-up many of the
younger male participants stated that they would consider pursuing genetic testing
independently in the future when they believed it would more directly impact their medical
care. Similarly, parenthood has been associated with greater testing uptake and described by
patients as a motivator for pursuing testing (Hadley et al., 2003; Finlay et al., 2008; Sharaf et al.,
2013). Finding lower rates of parenthood in the informed decline group aligns with this pattern.
The limited number of non-Caucasian individuals in this outcome group may suggest that
telephone counseling and testing kits are well-received by non-Caucasian individuals and, once
contact is successfully made, a facilitated protocol will lead to high rates of testing amongst
these demographics. The trends in the literature between education and testing uptake are
quite variable, with some research suggesting a positive relationship and other work finding
either no correlation or less perceived benefit for highly educated people (Henneman et al.,

2013; Sharaf et al., 2013). This study population was generally very highly educated and
education information was not available for a large portion of the at-risk family members which
should be considered when interpreting this result.
The level of informed decline (24%) was somewhat higher in this project than other
reported levels, which are typically below 10% (Christiaans et al., 2008). Much of the work on
cascade testing uptake has been done in strictly a BRCA1/2 testing setting or in familial
hypercholesterolemia (FH), a condition which can result in sudden death, and so motivations to
test are slightly different across these populations (Fehniger et al., 2013, Finlay et al., 2008,
Butrick et al., 2015, Christiaans et al., 2008; Sturm 2016). This pattern is further explored below.
Uptake Testing outcome group
This facilitated framework resulted in the highest uptake among demographics that
have historically shown the highest uptake without facilitation. The uptake testing outcome
group was generally older and more female. When compared to other outcome groups they
were slightly more likely to be parents, more likely to have a personal diagnosis of cancer, and
had the highest family participation rates. They were not more likely to be more closely related
to the index patient. The association with female sex and parenthood mirrors the patterns seen
in the informed decline outcome group and is supported by trends from other research (AktanCollan et al., 2000; Hadley et al., 2003; Finlay et al., 2008; Sharaf et al., 2013). Female sex has
frequently been associated with greater testing uptake (Aktan-Collan et al., 2000; Finlay et al.,
2008) and some have suggested that this is due to a feeling of responsibility as the family caregiver (d’Agincourt-Canning & Baird, 2006) but may also reflect the increased burden of several

mutations for female-specific tissues. Having a personal diagnosis of cancer logically increases
someone’s perceived risks of carrying the familial mutation and 8 of the 12 individuals with this
history who received testing were positive. These individuals also came from families that
exhibited higher rates of testing uptake on average. The familial participation variable was
designed to capture the general positive or negative sentiments in a family toward genetic
testing under the assumption that the decision of an individual to ultimately complete testing is
indicative of a positive inclination toward genetic testing generally. Six families tested all at-risk
relatives, and they comprise 30% of this outcome group.
Impacts of facilitation efforts on uptake
Although telephone genetic counseling has been shown to be non-inferior to traditional
genetic counseling, it has been consistently documented to result in marginally lower uptake of
genetic testing (Kinney et al., 2014; Kinney et al., 2016). The response to mailed, non-invasive
sampling kits has not been well examined in the literature. One previous study used both
telephone counseling and mailed buccal kits to test at-risk women with relatives who are
known BRCA1/2 carriers (Kinney et al., 2016). This project differed in that it relied on family
contact. Testing uptake rates were quite low (~28%) and significantly lower for the telephone
counseling and buccal kit group than the in-person group (Kinney et al., 2016). The uptake rates
we have documented are higher at 46%, suggesting that the addition of direct contact may
have directly improved uptake in study participants. Conditional uptake with telephone genetic
counseling has been documented between 84-87% (Butrick et al., 2015; Schwartz et al., 2014).
We documented a lower than expected conditional uptake rate of 76%. It has been suggested
that the separate step needed to obtain a sample, either traveling to a center for a blood draw

or completing and mailing a buccal kit, drives these lower uptake rates (Schwartz et al., 2014;
Kinney et al., 2016). This inference is supported by another study. A public health effort to test
family members for familial hypercholesterolemia in the Netherlands that employed traveling
genetics field workers and could provide house calls exhibited very high rates of familial testing
that plummeted by more than 80% once the project completed and the field workers were no
longer active (Louter at el., 2017). It is also possible that people who are reached by telephone
counseling include individuals who are less interested in genetic testing and would not have
attended a traditional in-person counseling session and their inclusion reduces conditional
uptake levels (Butrick et al., 2015).
It has been proposed that the gap in time between genetic counseling and testing allows
patients in facilitated settings to second guess their decisions or be influenced by external
opinions from family members (Kinney et al., 2016, Kanga-Parabia et al., 2018). We observed an
interesting pattern among families with high rates of informed decline. The majority of the
informed decline groups consists of individuals who did not return saliva kits after initially
agreeing to testing. During follow-up discussions it became clear that conversations between
family members had influenced decisions to withhold samples. These conversations involved
one miscommunication regarding a financial obligation for testing and others who appeared to
exhibit a decrease in perceived risk after discussing testing with relatives. The dynamics of
inter-familial communication about genetic testing is known to have significant influence on
uptake and other research has documented a similar change in decisions and reduction in
perceived risks after consulting with family (Ramirez 2015, Kanga-Parabia et al, 2018). The
number of families exhibiting complete assignment to a single outcome group and the

significant trend of increasing familial participation associated with individual uptake suggests
that families are consistent in their behavior, which may imply that there is an important role
for family communication in this highly facilitated testing framework.
Given our results and the patterns observed in other studies, more research is needed
to examine the reasons for lower testing uptake when mailed sample kits and telephone
counseling is employed. We encountered several issues with using these kits, including the
need to resend kits due to user error and a high rate of non-return of kits (23% of kits sent were
never returned). While mailed kits enabled the project to reach a large number of distant
relations across the USA and internationally, it is unclear if this format had an overall positive
impact on testing uptake.
Conclusions
While documenting statistically significant patterns was not possible for all variables
aside from familial participation, some conclusions may be inferred from the findings observed
here and comparisons made with other research. Cascade testing in its traditional form displays
biases with regards to who is informed and who pursues testing. While this project was able to
reach an array of distantly located family members, it was not able to eliminate the association
with low uptake of testing in individuals that are non-white, have low English language
proficiency, or live outside the USA. These patterns, when they have been addressed, have
been seen in other projects (Cheung et al., 2010; Fehniger et al., 2013). However, once contact
was established, uptake of testing among non-Caucasian individuals was high and so this

facilitated methodology may present a good option for these groups if the barrier of initial
contact can be surmounted.
This testing framework eliminated the sex-based risk notification pattern that has been
seen in family contact studies but still resulted in lower uptake of testing in males, a pattern
previously observed (Barrow et al., 2015). The facilitated protocol and direct contact methods
largely reduced any impact due to the degree of relationship to the index patient on either
notification of risk or testing uptake rates. This testing effort also shed light on the consistency
of behavior within families.
Taken as a whole, these results foster additional questions. Further investigation is
needed to determine the impact that communication within families has on decision making
and how this may lead to consistent behaviors within families during cascade testing. This may
be particularly relevant when mailed sample kits are employed due to the additional time built
in to the process and self-motivation required, which may promote indecision. Furthermore,
testing may benefit from closely examining families with the highest uptake to determine what
leads to the positive response to cascade testing in these groups. Lastly, this protocol improved
testing uptake for distant relatives and ensured informed decision making for males and
younger individuals who can be missed with traditional family contact but other demographic
variables were in accord with traditional testing efforts. More work is needed to improve
information gathering and contact of non-Caucasian, international, and non-English speaking
families, potentially by focusing on engaging index patients.
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